Mesoblast Limited (ASX:MSB) has extended its net loss by more than 30 per cent in the full 2014 financial year.
The stem cell therapy developer’s net loss widened to $80.9 million, as it invested in clinical development and manufacturing commercialisation.
Looking ahead the company has affirmed its strategy to create a broad product portfolio and enhance the likelihood of commercial success through strategic partnerships.
The results come in the same week Mesoblast appointed Paul Hodgkinson as its new chief financial officer, replacing Jenni Pilcher.
No dividends have been declared.
